Wellesta

What Wellesta does

Wellesta Holdings Pte Ltd is a Singapore-headquartered healthcare commercialization platform founded in 2019 by two executives with more than 70 years of combined multinational pharmaceutical experience. The company provides end-to-end market entry, regulatory registration, sales force deployment, brand management, and distribution services on behalf of pharmaceutical, biotechnology, medical device, diagnostics, OTC, and nutraceutical principals that want to commercialize across Southeast Asia, India, Europe, and MENA without building their own in-region infrastructure. As of 2022 headcount had reached 540+ employees, and operations are run through wholly-owned subsidiaries in Singapore, India, Indonesia, Malaysia, the Philippines, and Europe (Switzerland and Liechtenstein), with channel-partner coverage for MENA (Cureleads UAE/Beirut), Bangladesh (ACI Pharma), and selected SEA markets.

The product portfolio combines third-party partner brands with Wellesta-owned brands across four business verticals. Pharmaceuticals include hormonal IUDs (Pregna partnership) and partner-branded medicines. Medical Devices & Diagnostics cover ReDS Pro (FDA/CE-approved non-invasive lung fluid monitor from MitrAssist Lifesciences, now sold in SEA, India, and six European markets), BC-1 point-of-care EEG (BrainCapture), Butterfly iQ+ POCUS (Butterfly Network) for SEA and India, the iCTG wearable fetal monitor (Melody International), and the VECanDx ELISA bladder cancer detection kit (BioCheetah / Cooper Pharma). OTC and nutraceuticals include Bentrio nasal spray (Altamira Therapeutics), Nicotine Mini Lozenges (Rubicon Research, sold under the Wellesta brand), and the Wellesta TrueLife DTC portfolio in Malaysia. IntelliMed Healthcare Solutions — acquired September 2023 — supplies Medical Affairs, Medical Writing, and Real World Evidence generation, while the Indonesia Virtual Medical Representative (VMR) platform provides digital-first HCP engagement. Estaporin (Cyclosporin eyedrops via SGN Nanopharma Micellar Nano Particle technology, launched in Lebanon 2024) and Fx Mammo AI (breast cancer detection) extend the diagnostics footprint.

Wellesta's revenue model blends four streams: transaction-based product sales of partner brands, sales of Wellesta-owned brands, Contract Sales Organization (CSO) service fees in India through the Parazelsus alliance (which transferred 120 employees), and licensing/distribution agreements that include margins, milestones, and upfront fees. Pricing is conducted through B2B contract quotations rather than public list pricing. Strategic capital came via a Series B from Mitsui & Co., Ltd. and Japan Bank for International Cooperation (JBIC) in April 2023, supporting new product launches, geographic expansion, and potential manufacturing investments. Customer concentration is diversified across numerous named principals, with each relationship covering a defined territory or product rather than a single anchor account.

Name

Wellesta

Legal name

Wellesta Holdings Pte Ltd

Website

https://wellesta.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

251–500 employees

Short description

Wellesta is a Singapore-headquartered healthcare commercialization platform providing end-to-end regulatory, sales, marketing, and distribution services for pharmaceutical, medical device, diagnostics, OTC, and nutraceutical principals across Southeast Asia, India, Europe, and MENA.

Ownership category

akta.pro rank

Product category

Healthcare Commercialization Services

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210), Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (423450)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

OTC & Consumer Health Distributors (HLAIAJAC)

akta.pro secondary industries

Pharmacy Front-End & Sundries Distribution (Health & Wellness, Personal Care, Convenience) (CRAOAHAG), Vitamins, Minerals & Supplements (VMS) (HLAIADAN)

Keywords

• Pharmaceutical commercialization
• Medical device distribution
• Contract sales organization
• Medical affairs services
• Healthcare marketing services

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices7 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Supply Chain, Technology or R&D, Infrastructure

Revenue model

1. Product Sales — Partner Brands: Wellesta commercializes partner company products (pharmaceuticals, medical devices, diagnostics, OTC, nutraceuticals) in its operating regions, earning margin or fees on product sales. Products include ReDS Pro, BC-1 EEG, Butterfly iQ+ POCUS, iCTG fetal monitor, VECanDx ELISA, Bentrio nasal spray, hormonal IUD, Nicotine Mini Lozenges, and others. Wellesta handles registration, marketing, and distribution on behalf of principals.
2. Product Sales — Own/Wellesta Brands: Wellesta develops and sells products under its own brand names in select categories. Examples include Nicotine Mini Lozenges (sold under Wellesta brand), branded nutraceuticals through Wellesta TrueLife (Malaysia), and own-branded OTC products. Revenue is generated from direct product sales to distributors, pharmacies, or consumers.
3. Contract Sales Organization (CSO) Services: Wellesta provides sales force and marketing services to pharmaceutical and healthcare companies through its CSO operation, particularly in India (through Wellesta Healthcare Pvt. Ltd. and the Parazelsus alliance). Revenue is generated through service fees or retainer arrangements for deploying and managing sales teams on behalf of clients.
4. Licensing and Distribution Agreements: Wellesta enters into licensing and distribution agreements for innovative products (devices, diagnostics, therapeutics) in defined territories. Revenue mechanics include margins on sales, milestone payments, and upfront fees depending on the structure of each agreement.

Pricing tiers

Go-to-market motion4 records

Distribution channels5 records

Marketing channels4 records

Core offering

Wellesta is a Singapore-headquartered healthcare commercialization company that helps pharmaceutical, medical device, diagnostic, OTC, and nutraceutical companies enter and expand across Southeast Asia, India, Europe, and MENA markets. The company provides end-to-end brand management services including regulatory registration, sales force deployment, marketing, distribution, and post-launch optimization, operating its own direct subsidiaries in six countries and partner-led channels in others. Wellesta also develops and sells a limited portfolio of own-brand products (e.g., Nicotine Mini Lozenges) and acquires commercial rights to in-license innovative healthcare products for regional markets.

Product overview

Wellesta is a healthcare commercialization company headquartered in Singapore with direct market presence in Southeast Asia, India, and Europe, and partnering in MENA. The company operates as a value-added partner providing marketing and commercial support to healthcare companies through strategic partnerships and distribution agreements. Wellesta operates multiple business verticals under partner brands and own brands: Pharmaceuticals (affordable medicines through strategic partnerships), Direct-to-Consumer OTC and nutraceuticals, Medical Devices & Diagnostics (including ReDS™ Pro lung fluid monitor, BC-1 point-of-care EEG, Butterfly iQ+ POCUS, VECanDx diagnostic tests), and Medical Services (IntelliMed for Medical Affairs and Real World Evidence). Key products include ReDS™ Pro (non-invasive heart failure monitoring), BC-1 EEG device (AI-enhanced portable neurodiagnostics), Butterfly iQ+ ultrasound (whole-body POCUS), VECanDx bladder cancer test, Bentrio nasal spray, Nicotine Mini Lozenges, and Hormonal IUD. The company also offers digital health services including Virtual Medical Representative (VMR) and AI-powered tools like FathomX for breast cancer detection. Founded in 2019, Wellesta has grown to over 540 employees across 6 countries with operations spanning pharmaceutical, nutraceuticals, OTC, and medical devices under industry-proven leadership.

Differentiator

Problem solved

Functional benefit

Brands

• ReDS Pro: Non-invasive device for lung fluid measurement and monitoring using Remote Dielectric Sensing technology
• BC-1
• Bentrio
• VECanDx ELISA
• Butterfly iQ+/iQ+
• Wearable Fetal Monitor iCTG
• Nicotine Mini Lozenges
• Estaporin
• Hormonal IUD
• Fx Mammo
• IntelliMed

Products and services

• ReDS Pro Non-invasive lung fluid monitoring device using Remote Dielectric Sensing (ReDS) technology for heart failure management. FDA and CE-approved, delivers precise measurements in 45 seconds across hospital wards, outpatient clinics, post-acute facilities, and home monitoring settings. Distributed by Wellesta in SEA, India, and Europe.
• BC-1 Point-of-Care EEG Device

Quantifiable outcome

• ReDS Pro delivers precise lung fluid measurements within 45 seconds, enabling data-driven clinical decisions and timely interventions to reduce heart failure hospitalizations.
• +2 more outcomes

Named customers11 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature2 records

Partnerships

20 partnerships are on record, tiered core, moderate and minor.

• MitrAssist LifesciencescoreGTM or Marketing Partner · 29 August 2025Wellesta expanded its collaboration with MitrAssist Lifesciences to commercialize ReDS Pro (Remote Dielectric Sensing) — an FDA and CE-approved non-invasive lung fluid monitoring device for heart failure management — in six European markets (Austria, Belgium, France, Netherlands, Poland, Switzerland). The original 2024 agreement covered SEA and India. ReDS Pro delivers precise lung fluid measurements within 45 seconds and is used across hospitals, outpatient clinics, post-acute care, and home monitoring settings.
• Cooper PharmamoderateGTM or Marketing Partner · 31 January 2025Wellesta and Cooper Pharma (Morocco) entered into a sales and marketing agreement for VECanDx ELISA test — a bladder cancer early detection kit using five patented protein biomarkers via ELISA procedure — covering UAE, KSA, Rest of GCC (Kuwait, Bahrain, Oman, Qatar), Morocco, and Sub-Saharan Africa markets. Cooper Pharma is a leading Moroccan pharmaceutical company established in 1933 operating across Africa and the Middle East.
• BrainCapturecoreGTM or Marketing Partner · 30 January 2025Wellesta and BrainCapture expanded their agreement to market and distribute BC-1 — the first global point-of-care EEG device — in Vietnam, Cambodia, Brunei, and Laos markets of Southeast Asia. The original 2024 agreement covered SEA markets broadly and India. BC-1 is a portable, CE-marked mobile EEG system with smartphone app and cloud platform for remote neurological interpretation, enabling non-expert medical workers to collect high-quality EEG data with minimal training.
• PregnamoderateGTM or Marketing Partner · 13 December 2024Wellesta and Pregna signed an agreement for sales, marketing, and distribution of hormonal Intrauterine Device (IUD) with levonorgestrel 52mg in Southeast Asian markets. The IUD provides 5-year contraception protection, reduces heavy bleeding/Dysfunctional Uterine Bleeding, and can serve as emergency contraception within 5 days of unprotected intercourse. Pregna has impacted over 100 million women across 140 countries.
• Melody InternationalcoreGTM or Marketing Partner · 22 June 2024Wellesta and Melody International (Japan) signed an agreement for sales, marketing, and distribution of Wearable Fetal Monitor iCTG — a cloud-type mobile wireless fetal monitor already in use in Japan — for Asian markets. The device enables anywhere/anytime maternal and fetal monitoring, reduces emergency deliveries through early screening, and transmits real-time data during ambulance transfers. It also functions as a fetal Doppler.
• Escala MedicalmoderateGTM or Marketing Partner · 12 May 2024Wellesta announced collaboration with Escala Medical for the launch of an innovative pelvic prolapse treatment product developed by Escala Medical (led by Edit Goldberg) for women in Asia. The product addresses a significant unmet need in women's health, offering solutions for millions of women who suffer from pelvic prolapse.
• Butterfly NetworkcoreGTM or Marketing Partner · 12 March 2024Wellesta partnered with Butterfly Network (USA) to market and distribute Point-of-Care Ultrasound (POCUS) Butterfly Human and Butterfly Vet in South-East Asian countries. The Butterfly iQ+ is the world's first single probe, whole-body handheld POCUS device using Ultrasound-on-Chip technology, compatible with iOS and Android. A separate 2022 agreement with Abdul Latif Jameel Health covers India distribution of Butterfly iQ+ for the Indian market (targeting 1.2 million+ registered physicians).
• CureleadscoreGTM or Marketing Partner · 13 December 2023Wellesta acquired minority shares in Cureleads (UAE) — its strategic partner for MENA commercialization. Cureleads is a Dubai/Beirut-based pharmaceutical company aspiring to transform patient lives through specialty and rare disease treatments. Cureleads provides distribution and marketing of medicinal products in MENA. Wellesta and Cureleads have jointly commercialized VECanDx (bladder cancer detection) and Estaporin (Cyclosporin eyedrops) in Lebanon, Iraq, Egypt, and MENA markets.
• Advanced Chemicals Industries (ACI) PharmamoderateChannel Partner/ Reseller/ Distributor · 27 October 2023Wellesta Holdings and ACI Pharma (Bangladesh) entered a sales and marketing agreement for FathomX (AI-powered breast cancer detection), BioCheetah VECanDx (bladder cancer detection), Butterfly POCUS, and SKIIP (smoking cessation) for Bangladesh market. ACI Pharma is one of the largest pharmaceutical conglomerates in Bangladesh (6,000+ employees) and was introduced through deal advisor Mitsui & Co. (Asia Pacific).
• Ancom TruelifeminorChannel Partner/ Reseller/ Distributor · 20 October 2023Wellesta appointed Ancom Truelife (Malaysia) as distribution partner for Fx Mammo — an AI-powered breast cancer detection software — for government healthcare institutions in Malaysia. Wellesta and Ancom Truelife jointly sell and market the technology in the private sector, focusing on demand generation and patient awareness about early breast cancer detection.
• BioCheetahcoreGTM or Marketing Partner · 26 September 2023Wellesta and BioCheetah (Singapore) signed an agreement for Wellesta to commercialize VECanDx ELISA test — a non-invasive bladder cancer early detection kit identifying five patented protein biomarkers — in ASEAN, Indian subcontinent, MENA, EU, and LATAM. BioCheetah is a Singapore-based diagnostics startup with ISO13485 pilot production facility. Wellesta also partnered with BioCheetah for Bangladesh distribution via ACI Pharma.
• IntelliMed Healthcare SolutionscoreStrategic or Co-development Partner · 19 September 2023Wellesta acquired IntelliMed Healthcare Solutions as a Group company. IntelliMed is a scientific partner providing Medical Affairs, Medical Writing, and Real World Evidence generation for pharmaceuticals, medical devices, and nutraceuticals. It uses AI and digital tools to generate data-driven differentiation and support product market access. IntelliMed strengthens Wellesta's capability to provide end-to-end scientific support to Wellesta subsidiaries and client products.
• Abdul Latif Jameel HealthcoreGTM or Marketing Partner · 1 October 2022Abdul Latif Jameel Health (UAE) and Wellesta signed an agreement for marketing and distribution of Butterfly iQ+ Point-of-Care Ultrasound device in India. Wellesta registers and sells Butterfly iQ+ in India targeting the country's 1.2 million+ registered physicians. Abdul Latif Jameel Health is a healthcare division of diversified family business Abdul Latif Jameel, focused on accelerating healthcare inclusion in the Global South.
• Buergli Pharma Inc.coreStrategic or Co-development Partner · 1 November 2021Wellesta acquired a majority stake in Buergli Pharma Inc. (Philippines), which has operated as an established Philippine healthcare company for 15 years. The new entity — Wellesta Buergli Pharma Inc. — facilitates Wellesta's entry into the Philippine market, enables launch of in-licensed products, and adds own brand capabilities. Buergli brings seasoned pharmaceutical, OTC, and healthcare marketing professionals with strong industry ties.
• Altamira TherapeuticsmoderateGTM or Marketing Partner · 27 October 2021Wellesta and Altamira Therapeutics (Hamilton, Bermuda / Basel, Switzerland) signed a letter of understanding for marketing and distribution of Bentrio — a drug-free nasal spray for protection against airborne viruses and allergens — in India, Indonesia, Malaysia, Singapore, Taiwan, and Vietnam. A 2022 expansion added Philippines and Morocco. Bentrio forms a protective gel layer on nasal mucosa upon application. In Singapore, Bentrio is classified as a Class A medical device.
• Rubicon ResearchmoderateOEM/ Whitelabel/ Licensing Partner · 25 June 2021Wellesta and Rubicon Research (India/US/Canada) entered a licensing and supply partnership to launch Nicotine Mini Lozenges — a 12-week smoking cessation therapy (2 mg and 4 mg strengths, pack of 20, in Cherry, Cinnamon & Mint flavors) sold under Wellesta brand in Singapore, Indonesia, Malaysia, Philippines, and Thailand. Rubicon Research holds over 50 issued patents in drug delivery technologies and is a portfolio company of General Atlantic.
• SGN Nanopharma / CureleadsmoderateOEM/ Whitelabel/ Licensing Partner · 27 April 2021Wellesta, SGN Nanopharma (USA), and Cureleads entered a supply and licensing collaboration to launch nanotherapeutics for ophthalmic conditions — starting with dry eye disease — in SEA and MENA. SGN Nanopharma's Micellar Nano Particle (MNP) technology enhances absorption and efficacy. The first product (Estaporin, a generic Cyclosporin eyedrop using MNP technology) was launched in Lebanon in 2024 via Cureleads.
• TrueLife GroupcoreStrategic or Co-development Partner · 6 January 2021Wellesta group merged its Malaysia business with TrueLife Group of Malaysia. The merger created Wellesta TrueLife Sdn Bhd (nutraceutical DTC business) and Wellesta Healthcare Sdn Bhd (pharma business). TrueLife's strength in innovation, technology, and regulatory expertise in supplements complements Wellesta's regional commercial infrastructure. The merger accelerated Wellesta's market entry in Malaysia.
• Naari / NaariEstamoderateStrategic or Co-development Partner · 27 November 2020Wellesta Holdings and Naari Pte Ltd formed a joint venture — NaariEsta Pte Ltd — with Naari investing 65% and Wellesta 35%. NaariEsta is a vertically integrated, women's health-focused company operating in Singapore and Brunei markets. This gives Wellesta an ownership stake in a specialized women's health commercial entity.
• PT Citra Pharma IndonesiacoreStrategic or Co-development Partner · 1 December 2019Wellesta acquired majority shares and management control of PT Citra Pharma Indonesia (now PT Wellesta CPI Healthcare), which has operated successfully for 12 years as a partner with MNC players in pharma and healthcare in Indonesia. The company is led by Pak Freddy Hidajat as President Director and is based in Jakarta.

Scale indicators5 records

Recent moves10 records

Expansion highlights6 records

Broad incumbents

• Zuellig Pharma: Major Asian healthcare distribution and commercialization group covering pharmaceuticals, medical devices, and consumer health across SEA. Explicitly named as a competing employer for Wellesta's Philippines leadership, confirming direct overlap in regional pharma commercialization.
• DKSH: Swiss-listed market expansion services company with deep healthcare distribution and commercialization across Asia Pacific. Operates as the largest B2B healthcare commercialization platform in the region with established regulatory, sales force, and distribution infrastructure directly overlapping Wellesta's model.
• Aspen Pharmacare: South African-headquartered global specialty and branded generics pharmaceutical company with operations across emerging markets in Asia, Africa, and Latin America. Comparable as a multinational operating multi-country pharmaceutical commercialization in emerging markets.
• Biocon: Indian biopharmaceutical company with global presence across emerging markets including SEA, MENA, and parts of Europe through licensing and distribution partnerships. Comparable as an emerging-market pharma player utilizing regional distribution partners and own-brand commercialization.

Direct peers

• Mega Lifesciences: Thai-headquartered pharmaceutical and nutraceutical distribution and marketing company with presence across emerging markets in Asia, Africa, and CIS. Operates a comparable model of distributing and marketing partner products plus own brands in OTC and nutraceuticals.
• Hyphens Pharma: Singapore-headquartered specialty pharmaceutical and consumer healthcare company with operations across SEA through proprietary brands, in-licensed products, and B2B distribution. Directly comparable as a SEA-focused healthcare commercialization company with similar partner-brand and own-brand model.

Regional players

• Julphar (Gulf Pharmaceutical Industries): UAE-based pharmaceutical manufacturer and distributor covering MENA markets with branded generics, OTC, and consumer health portfolio. Comparable as a regional healthcare commercialization player with multi-country presence and partner-brand distribution model.

Emerging players

• Acino: Swiss-headquartered pharmaceutical company focused on licensing and commercialization of established brands across emerging markets in Middle East, Africa, Asia, and Latin America. Highly comparable business model to Wellesta's licensing/distribution approach.
• Eurofarma: Latin American pharmaceutical company expanding into emerging markets with multi-country commercialization, generics, and OTC portfolio. Comparable as a regional commercialization platform targeting emerging markets with branded pharmaceuticals and own-brand products.
• Syneos Health: Global clinical research and commercialization organization providing medical affairs, RWE, and contract sales services to pharma and medtech. Comparable for the medical affairs/RWE services (IntelliMed) and contract sales (CSO) components of Wellesta's offering.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/wellesta-healthcare-pte-ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles19 records

Subsidiaries11 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Wellesta